Browse by author
Lookup NU author(s): Dr Stuart Williamson,
Dr Alice Hartley,
Professor Rakesh Heer
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Castration resistant prostate cancer remains a major clinical burden and novel-therapeutic options are urgently required to improve survival. Tasquinimod is an orally-administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.
Author(s): Williamson SC, Hartley AE, Heer R
Publication type: Review
Publication status: Published
Journal: Drug Design, Development and Therapy
Print publication date: 21/03/2013
ISSN (print): 1177-8881
Publisher: DOVE MEDICAL PRESS LTD